The goal of this clinical trial is to learn if heart function remains normal after stopping heart failure medication in patients who have received chemotherapy.
If you agree to take part in this study, the following baseline tests and procedures will be performed on Day 1: * Your complete medical history will be recorded. * You will have a physical exam, including measurement of your vital signs (blood pressure, heart rate, and breathing rate). * You will complete a questionnaire about any symptoms you may be having. The questionnaire should take about 5-10 minutes to complete. * You will have an echocardiogram (ECHO) and an electrocardiogram (ECG) to check your heart function. * You will have blood (about 3 tablespoons) drawn for routine tests. If you can become pregnant, part of this blood draw will be used for a pregnancy test. To take part in this study, you must not be pregnant. * You will be given instructions on how to gradually wean yourself off of your heart failure medication. * You will be given a machine that you will use to measure your blood pressure at home. You will be asked to monitor your blood pressure and heart rate at home daily and keep the results in a diary. You should bring your diary to each study visit. At Month 1: * You will have a physical exam, including measurement of your vital signs. * You will complete the questionnaire about any symptoms you may be having. * You will have blood (about 2 teaspoons) drawn for routine tests. At Months 2, 4, 6, 12, 18, and 30: * You will have a physical exam, including measurement of your vital signs. * You will complete the questionnaire about any symptoms you may be having. * You will have an ECHO. * You will have blood (about 2 teaspoons) drawn for routine tests. At Months 3 and 5, you will have a telephone follow-up with a member of the research team. Length of Study Participation: You may continue taking part in the study for up to 6 continuous months with follow-up visits at Months 12, 18, and 30. You will no longer be able to take part if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions. This is an investigational study. Up to 45 participants will be enrolled in this study. All will take part at MD Anderson.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.
Electrocardiogram performed at baseline.
Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Determine the Percentage of Cancer Survivors That Maintain Left Ventricular Ejection Fraction (LVEF) ≥50% After Discontinuing Cardiac Medications: Beta Blockers, Angiotensin Converting Enzyme Inhibitors (ACE-I), or Angiotensin Receptor Blockers (ARB).
A withdrawal failure is defined as a decrease in the LVEF when cardiac medications are discontinued as determined by echocardiogram to LVEF\<50% or a decrease by 10% from baseline measurement. Maintenance of LVEF is defined as LVEF≥50%. LVEF was assessed at Baseline, Months 2, 4, 6, 12, 18, \& 30.
Time frame: A total of 30 months from enrollment date of each participant;
Risk Factors to Predict Early Decline of Myocardial Function During the Weaning of HF (Heart Failure) Medications.
To identify an increased troponin-I that can predict the possibility of HF medication withdrawal failure.
Time frame: A total of 30 months from enrollment date of each participant
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Telephone follow-up by study staff at months 3 and 5.